{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:29:21Z","timestamp":1783632561318,"version":"3.55.0"},"reference-count":53,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist today and need to be selected. A combination of the BCL2 inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib, acalabrutinib or zanubrutinib, while chemoimmunotherapy (CIT) is disappearing as a therapeutic option.<\/jats:p>","DOI":"10.1002\/hon.3145","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T21:16:34Z","timestamp":1686345394000},"page":"129-135","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["First line therapy of CLL"],"prefix":"10.1002","volume":"41","author":[{"given":"Michael","family":"Hallek","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine University of Cologn  Cologne Germany"},{"name":"Center for Integrated Oncology Aachen Bonn K\u00f6ln D\u00fcsseldorfe  Bonn Germany"},{"name":"Center of Excellence on \u201cCellular Stress Responses in Aging\u2010Associated Diseases\u201d University of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"The Surveillance E and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia \u2014 Chronic Lymphocytic Leukemia (CLL). [Internet].2021. Accessed 14 August 2021."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"issue":"2","key":"e_1_2_7_4_1","first-page":"65","article-title":"Incidence survey of leukemia in China","volume":"6","author":"Yang C","year":"1991","journal-title":"Chin Med Sci J"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.02.007"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.861"},{"issue":"1","key":"e_1_2_7_8_1","first-page":"89","article-title":"Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials","volume":"5","author":"Montserrat E","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900060103"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199805213382104"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0747-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.246"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01072-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215637"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509388"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1817073"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812836"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30788-5"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0313-8"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2005943"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00979"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009617"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30262-2"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00884-4"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211582"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00224-5"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.395"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.7015"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1513257"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.1"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.138"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1713976"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1313984"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761973"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30443-5"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1815281"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00894"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1900574"},{"key":"e_1_2_7_47_1","first-page":"LB1902","volume-title":"Fixed\u2010duration Ibrutinib and Venetoclax (I+V) versus Chlorambucil Plus Obinutuzumab (CLB+O) for First\u2010Line (1L) Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Phase 3 Glow Study","author":"Kater A","year":"2021"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400029"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0442"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.2282"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T06:32:07Z","timestamp":1692426727000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":53,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/hon.3145"],"URL":"https:\/\/doi.org\/10.1002\/hon.3145","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2023-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}